



10th Annual
**Microbiome
Movement Summit**
The Home of Accelerating Microbiome R&D

USA

June 23-25, 2025
Boston, MA

Showcasing the Latest Biological, Preclinical & Clinical Data to Supercharge R&D for GI, Oncology, Dermatology, CNS, Women's Health, & More

40+ World-Class Speakers, Including:



Ken Blount
Chief Scientific Officer
Rebiotix Inc., a Ferring Company



Jessica Schneider
Chief Scientific Officer
Corundum Systems Biology



Hervé Affagard
Co-Founder & Chief Executive Officer
MaaT Pharma



Nikole Kimes
Founder & Chief Executive Officer
Siolta Therapeutics



Denise Kelly
Investment Advisor
Seventure Partners



Travis Whitfill
Chief Operating Officer
Azitra



Paul Carlson
Principal Investigator
US Food & Drug Administration (FDA)



Vivek Lal
Founder, Executive Chairman & Chief Scientific Officer
Alveolus Bio



Todd Krueger
President & Chief Executive Officer
AOBioa

Lead Partner:



2025 Partners:



list labs



Anaerobe Systems
THE OXYGEN-FREE SPECIALISTS
A BIOLOG BRAND

GT GreenbergTraurig



JOIN 80+
MICROBIOME R&D
REPRESENTATIVES

CONTENTS

WHY JOIN IN
2025

JOIN THE
MICROBIOME
MOVEMENT

CONFIRMED 2025
SPEAKERS

AGENDA AT A
GLANCE

PRE-
CONFERENCE DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

2025 PARTNERS

PARTNER
WITH US

PRICING









REGISTER
NOW

Realizing the Potential of Microbiome R&D in New Indications

With **Seres Therapeutics**, **Ferring Pharmaceuticals**, and **MaaT Pharma** leading the advance of microbiome therapeutics with the first approvals and current late-stage clinical trial progress; and **Microviable Therapeutics**, **Freya Biosciences**, and **Concerto Biosciences** exploring exciting new indications beyond GI—such as oncology, dermatology, and women’s health—the field is poised for major breakthroughs. However, challenges in clinical translation, regulatory guidelines, and funding highlight the need for industry-wide collaboration.

The 10th Annual Microbiome Movement Summit returns to Boston, June 23-25, 2025, bringing you:

-  **40+ industry-leading speakers** from discovery, preclinical, translational, regulatory, and commercial sectors.
-  **Cutting-edge content** on microbiome R&D, AI-driven innovation, clinical advancements, and commercial strategies.
-  **Comprehensive sessions** on GI, oncology, CNS, dermatology, and women’s health, expanding conversations towards new indications and innovative research in microbiome R&D
-  **The returning start-up showcase** to highlight emerging companies and breakthrough technologies shaping the future of microbiome therapeutics.
-  **An innovation-fuelled awards ceremony** to celebrate the 10th year of this event series, and to recognize the outstanding achievements in microbiome research, innovation, and therapeutic development.
-  **Join the #1 microbiome industry summit** to advance your research, expand your network, and accelerate the next wave of microbiome-based therapeutics.

What’s New This Year?



Advancing Microbiome Therapeutics in Oncology: Uncover how companies like **MaaT Pharma**, **Microviable Therapeutics**, and **Kanvas Bio** are driving microbiome-based strategies to enable immunomodulation by optimizing the gut microbiota balance and enhance cancer immunotherapy.



Harnessing AI & Data Science for Microbiome Drug Discovery: Learn how **Pharmabiome**, **Jona** and **MD Anderson Cancer Center** are leveraging AI-driven analytics, metagenomics, and spatial transcriptomics to optimize patient selection, microbiome interventions, and precision therapeutics.



Emerging Innovations in Dermatology: Explore the latest breakthroughs from **Azitra**, **Concerto Biosciences**, and **AOBiome** in microbiome-based dermatological interventions to treat Netherton Syndrome and Atopic Dermatitis.



The Rise of Consumer Microbiome Products & Their Clinical Impact: Explore how direct-to-consumer microbiome innovations are influencing therapeutic breakthroughs. Hear from **Unilever**, **Fitbiomics**, **Nestlé Health Science** and **Floreya Biosciences** on navigating the regulatory landscape, ensuring scientific credibility, and bridging the gap between consumer success and clinical validation.



Microbiome-Based Respiratory & Inhaled Therapies: Discover how **Pulmobiotics** and **Alveolus Bio** are pioneering inhaled microbiome treatments for respiratory diseases, offering new approaches to lung health.

JOIN 80+ MICROBIOME R&D REPRESENTATIVES

CONTENTS

WHY JOIN IN 2025

JOIN THE MICROBIOME MOVEMENT

CONFIRMED 2025 SPEAKERS

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

2025 PARTNERS

PARTNER WITH US

PRICING



REGISTER NOW

Join the Microbiome Movement

Committed to Uniting the Entire Ecosystem to Bring Innovative Microbiome Products to Patients.
Join the community in 2025, with previously attending companies including:

10th Annual
Microbiome
Movement Summit
USA
June 23-25, 2025 | Boston, MA

JOIN 80+
MICROBIOME R&D
REPRESENTATIVES

CONSUMER



INVESTORS



TRUSTED MICROBIOME PARTNERS



ACADEMIC INSTITUTIONS



PHARMA



BIOTECH



GOVERNMENT & REGULATORY EXPERTS

CONTENTS

WHY JOIN IN 2025

JOIN THE
MICROBIOME
MOVEMENT

CONFIRMED 2025
SPEAKERS

AGENDA AT A
GLANCE

PRE-
CONFERENCE DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

2025 PARTNERS

PARTNER
WITH US

PRICING



REGISTER
NOW

40+ Expert Speakers for 2025

10th Annual
**Microbiome
Movement Summit** USA
June 23-25, 2025 | Boston, MA

JOIN 80+
MICROBIOME R&D
REPRESENTATIVES



Ada Lam
Researcher Analyst
Beacon Microbiome



Andres Cubillos-Ruiz
Co-Founder & Chief
Executive Officer
Florey Biosciences



Bernardo Cervantes
Co-Founder & Chief
Operating Officer
Concerto Biosciences



Chris McChalicher
Senior Vice President,
Head of CMC & Quality
Seres Therapeutics



Christopher Weidenmaier
Chief Scientific Officer
Mbiomics



Daniel Couto
Chief Operating
Officer
Vedanta Biosciences



David Friend
Chief Scientific Officer
Dare Bioscience



Denise Kelly
Investment Advisor
Seventure Partners



Greg Medlock
Senior Director, R&D
Vedanta Biosciences



Gregory McKenzie
Chief Executive Officer
Keep Bio



Hervé Affagard
Co-Founder & Chief
Executive Officer
MaaT Pharma



Jacob Nearing
Post Doctoral
Research Fellow,
Biostatistics
Harvard University



Jessica Schneider
Chief Scientific Officer
**Corundum Systems
Biology**



**Johan van Hylckama
Vlieg**
Chief Scientific Officer
& Co-Founder
Freya Biosciences



Jonathan Scheiman
Co-Founder & Chief
Executive Officer
Fitbiomics



Joshua Narrow
Director
The Conafay Group



Ken Blount
Chief Scientific Officer
**Rebiotix Inc.,
a Ferring Company**



Kevin Horgan
Head of Research &
Development
Melius MicroBiotics



Kyle Jacoby
Vice President,
Clinical Research
Kanvas Biosciences



Leo Grady
Founder & Chief
Executive Officer
Jona



Maria Lluch Senar
Co-Founder & Chief
Scientific Officer
Pulmobiotics



Mark Smith
Venture Lead
Seerave Foundation



Matthew Henn
Executive Vice
President & Chief
Scientific Officer
Seres Therapeutics



Nikole Kimes
Founder & Chief
Executive Officer
Siolta Therapeutics

CONTENTS

WHY JOIN IN
2025

JOIN THE
MICROBIOME
MOVEMENT

CONFIRMED 2025
SPEAKERS

AGENDA AT A
GLANCE

PRE-
CONFERENCE DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

2025 PARTNERS

PARTNER
WITH US

PRICING



REGISTER
NOW

40+ Expert Speakers for 2025

10th Annual
**Microbiome
Movement Summit** USA
June 23-25, 2025 | Boston, MA

JOIN 80+
MICROBIOME R&D
REPRESENTATIVES



Patricia Del Rio
Director of Business
Development
Mikrobiomik



Paul Carlson
Principal Investigator
**US Food & Drug
Administration (FDA)**



Philip Burnham
Chief Scientific Officer
Kanvas Biosciences




Rafik Fellague-Chebra
Executive Global Group
Medical Director
Novartis Oncology



Richard Ellis
Business Development
Director
Biose Industrie



Sam Costello
Chief Executive Officer
& Managing Director
BiomeBank



Sam Possemiers
Chief Executive Officer
MRM Health



Sarah Henning
Quality Control
Manager
List Labs



Sarah Tomkovich
Senior Scientist
Nestle Health Science



Shikha Snigdha
Senior Director,
Scientific Affairs
Unilever



Tim Langridge
Senior Scientist
Vedanta Biosciences



Todd Krueger
President & Chief
Executive Officer
AOBiome



Tomas De Wouters
Chief Executive Officer
PharmaBiome



Travis Whitfill
Chief Operating
Officer
Azitra



Vivek Lal
Founder, Executive
Chairman & Chief
Scientific Officer
Alveolus Bio

“It is and has always been the primary conference in the Microbiome space to keep me updated on the progress in the field of live biotherapeutic products”

Chief Scientific & Executive Officer, **Gusto Global**

“This conference was a fantastic opportunity to network with like-minded parties in the LBP space. The quality of the talks and the speakers were exceptional”

Head of Cultured Therapies, **BiomeBank**

CONTENTS

WHY JOIN IN
2025

JOIN THE
MICROBIOME
MOVEMENT

CONFIRMED 2025
SPEAKERS

AGENDA AT A
GLANCE

PRE-
CONFERENCE DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

2025 PARTNERS

PARTNER
WITH US

PRICING



**REGISTER
NOW**

Agenda at a Glance

PRE-CONFERENCE
WORKSHOP DAY
MONDAY, JUNE 23

Deep-Dive Networking Workshops

Bidirectional data sharing and discussion-based workshops to bring you the most current microbiome ecosystem updates, paired with networking sessions to strengthen your connections with key opinion leaders and field experts.

Workshop A

From Samples to Standards – Strengthening Microbiome Data for Clinical and Commercial Success

Lunch & Networking

Workshop B

Translating Microbiome Data into Actionable Biomarkers & Regulatory Approvals

End of Pre-Conference Day

CONFERENCE DAY ONE
TUESDAY, JUNE 24

Plenary

Securing Funding in 2025 & Mapping the Path to the Next LBP Approval

Morning Break & Networking

Track A:
GI & Infectious Diseases

Track B:
Indication Expansion

C. Difficile & GI Disorders

Cancer Therapies & Diagnostics

Lunch & Networking

Manufacturing Consistency, Stability, & Scalability

Skin Microbiome R&D for Dermatology

Afternoon Refreshments & Poster Networking Session

Plenary

Bridging the Gap: Clinical Innovations in Microbiome Therapeutics & The Convergence of Consumer Health with Pharmaceuticals

10th Anniversary Awards

End of Conference Day One

CONFERENCE DAY TWO
WEDNESDAY, JUNE 25

Plenary

Advancing Standards, Collaboration, & Innovation in Microbiome Research

Start-Up Showcase

Morning Break

Track A:
GI & Infectious Diseases

Track B:
Indication Expansion

GI Therapeutics Beyond C. Difficile

Breakthroughs in Probiotics & DTC for Microbiome Therapeutics

Lunch & Networking

Driving Innovation with Data

Women's Health & CNS Innovation with Gut-Brain Axis Modulation

Afternoon Refreshments & Networking

Plenary

Harness the Potential of Inhaled Microbiome Therapies in Respiratory Disease Treatment

End of Conference Day Two

CONTENTS

WHY JOIN IN 2025

JOIN THE MICROBIOME MOVEMENT

CONFIRMED 2025 SPEAKERS

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

2025 PARTNERS

PARTNER WITH US

PRICING

Pre-Conference Workshop Day | Monday, June 23

Morning Check-In: served with coffee + light breakfast

8.30

Workshop A

9.00

From Samples to Standards – Strengthening Microbiome Data for Clinical and Commercial Success

To drive microbiome-based therapeutics forward, we must address the critical gaps in data collection, statistical analysis, and validation. This workshop brings together key experts to discuss:

- Standardizing Sample Collection & Processing: Learn how improved chemistry and sequencing methods can enhance reproducibility, with insights from NIST and industry leaders
- The Impact of Biostatistics on Decision-Making: Understand how inadequate statistical analysis can mislead research and drug development, and explore biostatistical solutions tailored for microbiome studies
- Resolving Discrepancies in Bioinformatics Analyses: Examine case studies demonstrating how different computational methods yield varying conclusions from the same microbiome dataset
- Validating Microbiome-Based Biomarkers: Explore successful case studies where microbiome sequencing has been validated for diagnostic and therapeutic applications
- Engage in interactive discussions and gain practical strategies for improving microbiome data reliability, ensuring stronger translational success for therapeutics

Workshop Leaders



Denise Kelly
Investment Advisor
Seventure Partners



Jacob Nearing
Post Doctoral Research Fellow, Biostatistics
Harvard University

Lunch & Networking

12.00

Workshop B

1.00

Translating Microbiome Data into Actionable Biomarkers & Regulatory Approvals

As microbiome-based therapeutics move closer to regulatory pathways, overcoming data variability and establishing robust biomarkers is essential. This workshop will explore:

- Defining and Validating Microbiome Biomarkers: Discover best practices for developing clinically meaningful biomarkers and linking them to regulatory endpoints
- AI and Big Data in Microbiome Research: Learn how AI-driven analytics and spatial biology are shaping the next generation of microbiome-based therapeutics
- Regulatory Considerations for Microbiome Drug Development:
- Navigate the evolving FDA landscape and understand what it will take to translate microbiome biomarkers into approvable clinical endpoints
- Investor and Industry Perspectives: Gain insights from investors and industry leaders on which microbiome innovations hold the greatest potential for commercialization

Join this deep dive into the intersection of microbiome data science, regulatory strategy, and commercialization to accelerate your therapeutic pipeline.

Workshop Leaders



Ken Blount
Chief Scientific Officer
Rebiotix Inc., a Ferring Company



Tomas De Wouters
Chief Executive Officer
PharmaBiome

Close of Pre-Conference Workshop Day

4.00

CONTENTS

WHY JOIN IN 2025

JOIN THE MICROBIOME MOVEMENT

CONFIRMED 2025 SPEAKERS

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

2025 PARTNERS

PARTNER WITH US

PRICING



REGISTER NOW

Conference Day One | Tuesday, June 24



7.00 **Morning Check-In:** served with coffee + light breakfast



Daniel Couto
Chief Operating Officer
Vedanta Biosciences

8.05 **Chair's Opening Remarks**

Securing Funding in 2025 & Mapping the Path to the Next LBP Approval



Ken Blount
Chief Scientific Officer
Rebiotix Inc., a Ferring Company

8.10 **Pioneering the Future of Microbiome Therapeutics: Assessing Clinical Progress & Outlining Market Opportunities**

- Evaluating clinical progress by analysing existing approvals and late-stage clinical trial candidates
- Unlocking new market opportunities in oncology, women's health, and metabolic disorders while navigating pharma investment trends
- Assessing the current progress of incorporating advanced technologies like AI-driven microbiome analysis, synthetic biology, and scalable manufacturing to accelerate innovation



Richard Ellis
Business Development
Director
Biose Industrie

8.30 **Microbiome Products (LBP & NGP) Development & Manufacturing**



Ada Lam
Researcher Analyst
Beacon Microbiome

9.00 **Microbiome Clinical Landscape Review**

- Explore the clinical landscapes of Microbiome drug development
- Reveal therapeutic modalities, therapy-specific properties, and disease indications gaining traction
- Give an analysis of the commercial landscape driving the clinical development of the space



Hervé Affagard
Co-Founder & Chief
Executive Officer
MaaT Pharma

9.30 **MaaT013: The First Phase 3 Trial for Microbiome Therapy in Hemato-Oncology**

- Discussing the ongoing pivotal Phase 3 ARES trial for MaaT013 in patients with acute Graft-versus-Host Disease (GI-aGvHD) and its significance as the first global Phase 3 trial for a microbiome-based therapy in hemato-oncology
- Highlighting the Orphan Drug Designation from both the FDA and EMA, and the positive outcomes from the Data Safety Monitoring Board (DSMB) review.
- Exploring the positive Phase 3 ARES results, evaluating MaaT013's unprecedented efficacy as a third-line treatment for GI-aGvHD

10:00 **Fireside Chat: Unlocking Pharma & Investor Buy-In**

- Understanding the cautious approach of large pharma towards microbiome investments and the factors shaping their decisions
- Analyzing recent strategic partnerships and investment trends to uncover what drives value in microbiome-based innovations
- Discussing key considerations for forging successful partnerships with big pharma and aligning biotech strategies with industry needs to drive mutual growth



Denise Kelly
Investment Advisor
Seventure Partners



Mark Smith
Venture Lead
Seerave Foundation



Rafik Fellague-Chebra
Executive Global Group Medical Director
Novartis Oncology



Jessica Schneider
Chief Scientific Officer
Corundum Systems Biology



10:30 **Morning Break & Networking**

Make the most of this morning networking session to reconnect with your industry and meet fellow microbiome pioneers. Use this opportunity effectively to connect with cross-industry stakeholders and form important connections for expediting your platform development

CONTENTS

WHY JOIN IN
2025

JOIN THE
MICROBIOME
MOVEMENT

CONFIRMED 2025
SPEAKERS

AGENDA AT A
GLANCE

PRE-
CONFERENCE DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

2025 PARTNERS

PARTNER
WITH US

PRICING



REGISTER
NOW

Conference Day One | Tuesday, June 24

Advancing GI & Infectious Diseases Track	Expanding Pipelines with New Indications Track
Revolutionize GI Therapeutics: Pioneering Late-stage Developments & Innovative Treatments for C. Difficile and GI Disorders	Microbiome’s Role in Cancer Therapy: Unveiling the Gut Microbiome’s Impact on Cancer Diagnostics & Treatment Efficacy
<div>11:30 Clinical Update on C. diff Candidate RBX2660</div> <div><ul style="list-style-type: none">Discussing the pivotal Phase 3 trial results of RBX2660, demonstrating its superior efficacy in reducing recurrence of Clostridioides Difficile Infection (CDI)Explore the significance of FDA approval and breakthrough therapy designation for RBX2660, and its impact on accelerating the development and availability of this microbiome-based therapeuticFuture Directions and Applications: Examine the potential expansion of RBX2660’s use in other high-risk patient populations and the ongoing efforts to address unmet medical needs in gastrointestinal health</div> <div>Ken Blount, Chief Scientific Officer, Rebiotix Inc., a Ferring Company</div>	<div>11:30 KAN-001, a Complex Consortium Live Biotherapeutic Product to Augment Cancer Therapy</div> <div><ul style="list-style-type: none">From FMTs to LBPs: A reverse translational approach to creating an optimized and sustainable therapy to augment patients’ immune systems and response to cancer immune checkpoint therapyKAN-001 optimization and preclinical testingKAN-001 strains in patients: assessing existing KAN-001 strain-level clinical engraftment data de-risks development</div> <div>Kyle Jacoby, Vice President, Clinical Research, Kanvas Bio</div>
<div>12:00 Beyond Antibiotics: Developing the Potential of Microbiome-Based Treatments</div> <div><ul style="list-style-type: none">Presenting Phase 3 efficacy and safety data for MBK-01, a non-antibiotic therapy for Clostridioides difficile infectionExploring real-world evidence findings and insights from the compassionate use programExpanding clinical research efforts into new therapeutic areas for MBK-01</div> <div>Patricia del Rio, Director of Business Development, Mikrobiomik</div>	<div>12:00 Roundtable Discussion: Charting the Future of Microbiome-Driven Cancer Therapy: Integration, Innovation & Translation</div> <div><ul style="list-style-type: none">Reflect on key learnings from MaaT013 and KAN-001 to evaluate what defines a clinically successful and scalable microbiome-based oncology therapyDiscuss the current barriers to integrating microbiome interventions with standard-of-care cancer therapies, particularly in immune-oncology and GI cancersIdentify priority areas for biomarker development, patient stratification, and regulatory clarity to accelerate clinical translationExplore what’s needed to move from trial success to routine clinical practice—considering manufacturing, commercialization, and payer engagement</div>

12.30 Lunch & Networking

Mapping Out the Microbiome & Strategies for Manufacturing Consistency, Stability & Scalability	The Skin Microbiome Revolution for Advanced Dermatological Treatments
<div>1:30 A Platform for Rationally Designing and Controlled Manufacturing of Complex Consortia Products that combine the Functional Diversity and Activity of Healthy Microbiomes with Scalable, Consistent and MoA-targeted Consortia</div> <div><ul style="list-style-type: none">Enabling precise identification and quantification of individual strains within complex consortia, allowing for potency assessment and process control in manufacturingAddressing co-culture challenges by stabilizing microbial communities through rational product design and advanced fermentation strategiesEnsuring scalability, reproducibility, and quality control of high-diversity microbial therapeuticsStrategically integrating strain-specific mechanisms with host-microbiome interactions</div> <div>Christopher Weidenmaier, Chief Scientific Officer, Mbiomics</div>	<div>1:30 Exploring ENS-002: A Microbiome-Based Therapy for Atopic Dermatitis</div> <div><ul style="list-style-type: none">Targeting Staphylococcus aureus by using a combination of three microbial strains to restore balance to the skin microbiome without immune suppressionEvaluating ENS-002’s safety and tolerability in Phase 1 clinical trials, with a focus on its impact on S. aureus abundance and atopic dermatitis symptomsAnticipating Phase 2 trial results, which will provide further insights into ENS-002’s efficacy and its potential to become a transformative treatment for atopic dermatitis</div> <div>Bernardo Cervantes, Co-Founder & Chief Operating Officer, Concerto Biosciences</div>

CONTENTS

WHY JOIN IN 2025

JOIN THE MICROBIOME MOVEMENT

CONFIRMED 2025 SPEAKERS

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

2025 PARTNERS

PARTNER WITH US

PRICING

Conference Day One | Tuesday, June 24

2:00 Advancing Assay Development for Multi-Strain Live Biotherapeutic Products

- The next generation of complex live biotherapeutic products demands advanced analytical approaches beyond sequencing to accurately assess potency, efficacy, and safety
- Kanvas has developed a spatial imaging platform that provides unprecedented resolution in evaluating microbial interactions and the host-microbe interface
- This technology enhances strain isolation, refines process development by characterizing strain-strain interactions, and enables more precise potency assays to meet evolving regulatory and clinical validation requirements

Philip Burnham, Chief Scientific Officer, Kanvas Biosciences

2:30 Advancing Assay Development for Multi-Strain Live Biotherapeutic Products

- Developing assays to evaluate the potency of multi-strain LBPs
- Key considerations for potency assay development and validation for late-stage clinical studies of LBPs

Greg Medlock, Senior Director, R&D, Vedanta Biosciences

2:00 Development of ATR-12, an Engineered Strain of S. Epidermidis, for Netherton Syndrome

- Netherton syndrome is a rare, severe skin disease caused by missing LEKTI protein
- ATR-12 is an engineered strain that delivers LEKTI to the skin to treat Netherton syndrome
- Initial safety results of an ongoing Phase 1 clinical study of ATR-12 in adult Netherton syndrome patients

Travis Whitfill, Chief Operating Officer, Azitra

2:30 Advancing Topical Therapies & Harnessing Ammonia Oxidizing Bacteria for Skin Health

- Exploring the therapeutic mechanism of Ammonia Oxidizing Bacteria (AOB) in regulating inflammation and immunomodulatory activity on the skin
- Understanding how AOB treatment supports a balanced, anti-inflammatory environment and enhances skin health
- Phase 2 clinical results of B244, demonstrating significant reductions in pruritus, improvements in Atopic Dermatitis (AD), and strong durability of treatment effects in patients with mild-to-moderate AD and associated itch; Preparations for Phase 3

Todd Krueger, President & Chief Executive Officer, AOBiome

“Attending the Microbiome Movement meeting offers significant value by providing opportunities to learn about host-microbiome interactions and new technologies, discover and develop LBPs, form partnerships, and gain competitive insights. The conference also enables attendees to explore opportunities in various markets, such as LBP manufacturing, spatial biology, cancer immunotherapy, and inflammatory bowel disease, fostering innovation and growth in the emerging microbiome field.”

Kyle Jacoby, Vice President, Clinical Research, Kanvas Biosciences

CONTENTS

WHY JOIN IN 2025

JOIN THE MICROBIOME MOVEMENT

CONFIRMED 2025 SPEAKERS

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

2025 PARTNERS

PARTNER WITH US

PRICING



3:00 Afternoon Break & Scientific Poster Session

This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of preclinical, translational, and clinical scientists eager to hear the latest advancements in Microbiome therapeutic development, you will have the opportunity to display a poster presenting your own work and innovations. Get in touch to apply: info@hansonwade.com

Bridging the Gap: Clinical Innovations in Microbiome Therapeutics & The Convergence of Consumer Health with Pharmaceuticals

3:30 Panel Discussion: Scaling Up Manufacturing for Clinical Trials of LBPs

- Scaling up LBP production from preclinical to late-stage clinical trial quantities by maintaining microbial consistency, stability, and product quality at larger scales
- Managing the supply chain and logistics for late-stage trials by ensuring reliable and timely delivery of LBPs, including temperature-sensitive storage, transportation, and distribution to multiple clinical sites
- Navigating regulatory requirements during late-stage trials by balancing manufacturing compliance with the strict demands for clinical-grade products and preparing for commercialization



Chris McChalicher
Senior Vice President, Head of CMC & Quality
Seres Therapeutics



Christopher Weidenmaier
Chief Scientific Officer
Mbiomics



Tim Langridge
Senior Scientist
Vedanta Biosciences



Sarah Henning
Quality Control Manager
List Labs

4:00 Development of Microbiological Examination Methods for Live Biotherapeutic Products

- Complications with traditional methods
- Existing guidance for objectionable organism testing in LBPs
- Alternative methods for detecting and identifying objectionable organisms

4:30 Panel Discussion: From Consumer Success to Clinical Impact: How Direct-to-Consumer Microbiome Products Are Shaping Therapeutic Breakthroughs

- Evaluating clinical trial strategies for direct-to-consumer microbiome products: costs, regulatory pathways, and scientific credibility
- Analyzing the economic viability of trial-based models in the DTC space: profitability, investor interest, and commercialization speed
- Navigating marketing and regulatory constraints for microbiome therapeutics in a consumer-driven landscape



Andres Cubillos-Ruiz
Co-Founder & Chief
Executive Officer
Florex Biosciences



Jonathan Scheiman
Co-Founder &
Chief Executive Officer
Fitbiomics



Leo Grady
Founder & Chief
Executive Officer
Jona



Shikha Snigdha
Senior Director,
Scientific Affairs
Unilever



Daniel Couto
Chief Operating Officer
Vedanta Biosciences

5:00 Chair's Closing Remarks & End of Day 1



5:05 10th Annual Microbiome Movement Awards

The 10th Annual Microbiome Movement Awards will celebrate groundbreaking achievements and exceptional contributions in microbiome research and therapeutics. This prestigious event highlights the innovative companies, researchers, and thought leaders driving the microbiome field forward. Through a series of award categories, the ceremony will recognize advancements in microbiome-based drug discovery, novel therapeutic applications, pioneering technologies, and leadership within the microbiome ecosystem.

6:05 End of Day 1

CONTENTS

WHY JOIN IN
2025

JOIN THE
MICROBIOME
MOVEMENT

CONFIRMED 2025
SPEAKERS

AGENDA AT A
GLANCE

PRE-
CONFERENCE DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

2025 PARTNERS

PARTNER
WITH US

PRICING



REGISTER
NOW



7.00 Morning Check-In
Served with coffee and a light breakfast



Daniel Couto
Chief Operating Officer
Vedanta Biosciences

7.55 Chair's Opening Remarks

Advancing Standards, Collaboration & Innovation in Microbiome Research

8.00 Roundtable: Advancing Microbiome Therapeutics: Insights from the MTIG and EMIH Collaboration

- How can harmonized regulatory frameworks benefit microbiome therapeutics across different regions, and what specific steps can be taken to achieve this harmonization?
- What innovative strategies can be employed to accelerate the development of microbiome-based therapies through international collaboration, and how can these strategies be effectively implemented?
- How can expanding access to microbiome therapies benefit the economy and healthcare systems, and what measures are necessary to ensure equitable access to these innovative treatments?



Johan van Hylckama Vlieg
Chief Scientific Officer &
Co-Founder
Freya Biosciences



Joshua Narrow
Director
The Conafay Group



Hervé Affagard
Co-Founder & Chief
Executive Officer
MaaT Pharma



Nikole Kimes
Founder & Chief
Executive Officer
Siolta Therapeutics



Paul Carlson
Principal Investigator
US Food & Drug
Administration (FDA)

8:30 Regulatory Considerations for Microbiome-Based Therapeutics

- Interpreting the latest FDA guidance on LBPs, FMT-based therapies, and the shifting regulatory framework for microbiome drugs
- Addressing key hurdles in clinical trial design, potency validation, and manufacturing standards to meet FDA expectations
- Preparing for future regulatory trends with insights on accelerated approval pathways, real-world data integration, and evolving safety requirements



Rafik Fellague-Chebra
Executive Global Group
Medical Director
Novartis Oncology

9:00 The Microbiome's Role in Gastrointestinal Cancers

- Exploring the Microbiome & Colorectal Cancer: How gut microbiota modulate colorectal cancer risk and progression, evaluating the influence of microbial metabolites (e.g., butyrate) on tumor microenvironment and elucidating microbiome interactions with immunotherapy and chemotherapy response
- Other GI Cancers (Pancreatic, Gastric & Esophageal): exploring key microbiome-driven mechanisms in upper GI cancers, the role of bacterial dysbiosis in inflammation and tumorigenesis, and exploring current and emerging microbiome-targeted therapeutic strategies
- Translating Microbiome Research into Oncology Practice: including strategies for microbiome modulation, the potential for microbiome-based biomarkers in GI cancer detection and challenges and future directions in integrating microbiome science into cancer care



Matthew Henn
Executive Vice President &
Chief Scientific Officer
Seres Therapeutics

9:30 Breakthrough in GI-Derived Bloodstream Infection Reduction: SER-155's FDA Designation

- Highlighting the significant reduction in bacterial bloodstream infections demonstrated in Phase 1b trials of SER-155 and its impact on patient outcomes
- Discussing the significance of FDA breakthrough therapy designation and fast track status for expedited development and regulatory collaboration
- Exploring the future development plans for SER-155, including its potential applications in various high-risk patient populations

CONTENTS

WHY JOIN IN
2025

JOIN THE
MICROBIOME
MOVEMENT

CONFIRMED 2025
SPEAKERS

AGENDA AT A
GLANCE

PRE-
CONFERENCE DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

2025 PARTNERS

PARTNER
WITH US

PRICING



REGISTER
NOW

Conference Day Two | Wednesday, June 25

10.00 Start-Up Showcase

Immerse yourself in a showcase of cutting-edge research and technologies as short-listed microbiome start-ups unveil their unique approaches to drug development. You, and a judging panel of experts, will meet the brilliant minds behind microbiome start-ups, understanding their expertise, commercial strategies for success and passion that drives their mission to revolutionize today's drug development landscape.

With prizes at stake, join us for a dynamic session where microbiome start-ups take center stage and a panel of VC's and investors decide who to award as the winner of the **Microbiome Movement Start-Up Showcase 2025!**

Expert Investment Panel Includes



Denise Kelly
Investment Advisor
Seventure Partners



Jessica Schneider
Chief Scientific Officer
Corundum Systems Biology



Rafik Fellague-Chebra
Executive Global Group Medical Director
Novartis Oncology

Start-up Showcase Finalists Announced!



Kevin Horgan
Head of Research & Development
Melius MicroBiotics



Zoe Watson
Co-Founder & Chief Executive Officer
Microvitality



10:30 Morning Networking Break
An opportunity to network, discuss and collaborate with like-minded leaders

CONTENTS

WHY JOIN IN 2025

JOIN THE MICROBIOME MOVEMENT

CONFIRMED 2025 SPEAKERS

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

2025 PARTNERS

PARTNER WITH US

PRICING



REGISTER NOW

Conference Day Two | Wednesday, June 25

Advancing GI & Infectious Diseases Track	Expanding Pipelines with New Indications Track
<div>Progressing Microbiome Therapeutics for GI & Infectious Diseases Beyond C.Difficile</div> <div><div>11:00 KeepBio: A Microbiome-Targeted Therapy to Reduce Healthcare-Associated Infections</div><div><ul style="list-style-type: none">Synbiotic approaches lead to reproducible changes in patient microbiomesWorking to leverage glycan-microbe specificity drives decolonization in pathogendominated patientsCommercializing rapidly and bringing innovation to bedsides safely<div>Gregory McKenzie, Chief Executive Officer, KeepBio</div></div></div> <div><div>11:30 Advancing Microbiome Therapeutics: The Role of Co-cultured Therapies in Ulcerative Colitis & Beyond</div><div><ul style="list-style-type: none">Evaluating the promise of co-cultured microbiome therapies.Emergent function of diverse consortiaExploring a case study of the development of a co-cultured therapy for ulcerative colitisHighlighting regulatory and manufacturing challenges and solutions<div>Sam Costello, Chief Executive Officer & Managing Director, BiomeBank</div></div></div> <div><div>12:00 Roundtable Session: Mission Microbiome: Designing the Next Breakthrough Therapeutic for GI & Infectious Disease</div><div><div>Participants will form small "biotech taskforce" teams. Each team's mission is to design and pitch a future-forward microbiome therapeutic concept addressing a high priority unmet need in GI or infectious diseases</div><div><ul style="list-style-type: none">Target Prioritization: What indication or patient population should be the next focus for microbiome therapeutics, and why?Modality & Mechanism: Should your therapy use co-cultured consortia, synbiotics, engineered strains, or another platform? What's the core mechanism of action?Regulatory & Clinical Strategy: What endpoints and biomarkers will be key to regulatory success, and how do you de-risk development early on?Commercial Viability: What's your plan for manufacturing, delivery (oral, capsule, etc.), and payer buy-in to make this therapy viable in real-world healthcare systems?</div></div></div>	<div>Harnessing Probiotics to Modulate the Microbiome: Next-Gen Innovations & Engineered Solutions for Microbiome Resilience</div> <div><div>11:00 Advancing Next-Generation Probiotics: Translating FitBiomics' Clinical & Preclinical Data into Performance and Health Innovations</div><div><ul style="list-style-type: none">Harnessing the Gut Microbiome for Human Performance – Exploring FitBiomics' latest clinical and preclinical data on next-generation probiotics derived from elite athletes and their potential to enhance metabolism, endurance, and recoveryBridging the Gap Between Preclinical Insights and Clinical Validation – Lessons learned from translating microbiome-based discoveries into human trials, including biomarker-driven approaches to assess efficacyMechanisms of Action: Understanding How Novel Probiotics Drive Health Benefits – Unpacking the functional impact of specific microbial strains on gut health, immune modulation, and systemic health improvementsRegulatory & Commercialization Strategies for Microbiome-Based Interventions – Addressing the path from research to real-world applications, including regulatory considerations, consumer adoption, and future innovation in the probiotics space<div>Jonathan Scheiman, Co-Founder & Chief Executive Officer, Fitbiomics</div></div></div> <div><div>11:30 Diet & Lifestyle Factors that Influence Spore Levels & Stability Over Time</div><div><ul style="list-style-type: none">Environmental factors such as diet and lifestyle influence the donor microbiotaExploring how these factors associate with spore levels across individualsEvaluating factors that influence stability of spore levels over time within donors<div>Sarah Tomkovich, Senior Scientist, Nestlé Health Science</div></div></div> <div><div>12:00 Engineering Probiotics to Safeguard the Gut Microbiome During Antibiotic Therapy</div><div><ul style="list-style-type: none">Impact of Antibiotics on the Gut Microbiome: Exploring how common antibiotic treatments can disrupt beneficial gut bacteria, leading to potential health issuesIntroduction to FLR-101: Presenting FLR-101, an engineered yeast strain designed to produce enzymes that degrade specific antibiotics in the gut, thereby protecting the microbiome without compromising the systemic efficacy of the treatmentRegulatory Strategy and Medical Food Classification: Discussing Florey's unique approach to navigating regulatory pathways by developing FLR-101 as a medical food, aiming for efficient market entry and broad accessibilityFuture Directions in Engineered Probiotics: Outlining plans for expanding the application of Florey's synthetic biology platform to develop additional probiotics targeting various health conditions influenced by the gut microbiome<div>Andres Cubillos-Ruiz, Co-Founder & Chief Executive Officer, Florey Biosciences</div></div></div>

CONTENTS

WHY JOIN IN 2025

JOIN THE MICROBIOME MOVEMENT

CONFIRMED 2025 SPEAKERS

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

2025 PARTNERS

PARTNER WITH US

PRICING



REGISTER NOW



12.30 Networking Lunch

13:25 Announcing the Winner of the Start-Up Showcase!

Using Data to Drive Innovation & Modulating Gut-Brain Axis for CNS Indications

1:30 Learnings from Clinical Development with MH002 in IBD and Translation to LBP Development for Parkinson's Disease

- Reviewing Phase 2 clinical data of MH002, a next-generation microbiome therapy utilizing MRM Health's CORAL® Technology, combining six commensal strains for targeted action in Ulcerative Colitis (UC) and Pouchitis
- Lessons learned and highlights on its ability to restore gut microbiome balance and improve clinical outcomes
- Translation of knowhow from clinical program to develop LBPs for Parkinson's Disease; update on preclinical data

Sam Possemiers, Chief Executive Officer, MRM Health

2:00 Leveraging AI & Big Data in Microbiome Drug Discovery

- Analyzing gut microbiome data is incredibly challenging due to the wide variation in microbial ecosystems found in the gut and due to the incredible explosion of scientific papers linking the gut microbiome to various diseases and health conditions (now more than two thousand peer-reviewed studies per month in PubMed). For the first time, large language models (a form of AI) offer us the ability to synthesize all of the world's scientific knowledge to fully analyze gut microbiome data for an individual.
- The extraction of the complete published scientific knowledge of the microbiome makes it possible to develop a microbiome digital twin that can be used to digitally simulate the effects of different interventions on a trial subject with a known microbiome and predict drug therapeutic efficacy prior to treatment in the trial
- This AI technology for both analysis and digital twinning unlocks new opportunities and avenues for drug targets, therapeutic development, clinical trial design, patient recruitment and biomarker development

Leo Grady, Founder & Chief Executive Officer, Jona

Translating Microbiome Learnings to Women's Health & Gut-Brain Axis for CNS Indications

1:30 Impact of Vaginal Products on the Vaginal Microbiome

- Regulatory insights into clinical assessments during clinical trials
- Clinical trial data showcasing contraceptive studies and impact on the microbiome
- New approaches to Improving vaginal health

David Friend, Chief Scientific Officer, Daré Bioscience

2:00 Leveraging Microbial Immunotherapies for Bacterial Vaginosis: Innovations with the DYSCOVER Platform

- Developing microbial immunotherapies for Bacterial Vaginosis (BV) using the DYSCOVER platform to address the imbalance in the vaginal microbiome and reduce inflammation
- Leveraging proof-of-concept studies (DYSCOVER-I and Dyscover II) to demonstrate the efficacy of Lactobacillus strains in engrafting the vaginal tract and displacing dysbiotic microbiomes
- Mitigating serious consequences in pregnant women by reducing the recurrence of BV and associated risks such as premature rupture of membranes, preterm birth, intra-amniotic infection, low birth weight, and miscarriage

Johan van Hylckama Vlieg, Chief Scientific Officer & Co-Founder, Freya Biosciences

CONTENTS

WHY JOIN IN 2025

JOIN THE MICROBIOME MOVEMENT

CONFIRMED 2025 SPEAKERS

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

2025 PARTNERS

PARTNER WITH US

PRICING



REGISTER NOW



2:30 Afternoon Networking Break

Harnessing the Potential of Inhaled Microbiome Therapies in Respiratory Disease Treatment



Maria Lluch Senar
Co-Founder & Chief
Scientific Officer
Pulmobiotics

3:00 Engineering Microbiome-Based Inhaled Therapies for Respiratory Diseases

- Addressing the complexities of selecting the right bacterial chassis for inhaled microbiome-based therapies to prevent rapid clearance by the immune system and respiratory physiology
- Exploring Pulmobiotics' approach to engineering bacteria to produce human proteins like cytokines and interleukins to stimulate targeted immune responses in conditions like lung cancer
- Highlighting Pulmobiotics' innovative use of microbiome-derived bacteria, such as their Mycoplasma pneumoniae-based candidate, to treat infectious diseases and disrupt biofilms in combination with standard antibiotics



Vivek Lal
Founder, Executive
Chairman & Chief Scientific
Officer
Alveolus Bio

3:30 Inhalation of Lactobacilli for COPD & BPD Treatment

- Targeting lung inflammation by using a Lactobacilli blend to modulate inflammatory markers and restore lung function
- Investigating preclinical results by demonstrating improvements in lung structure and function in both BPD and COPD mouse models
- Anticipating clinical trials by preparing for human safety testing and further evaluation of the therapeutic potential of this live biotherapeutic



Daniel Couto
Chief Operating Officer
Vedanta Biosciences

4:00 Chair's Closing Remarks & End of Conference

High quality presentations, well attended by representatives of all stages of development, many opportunities for interaction

Senior Director, R&D Strategic Lead, Gastrointestinal & Microbiome, **Ferring Pharmaceuticals**

CONTENTS

WHY JOIN IN
2025

JOIN THE
MICROBIOME
MOVEMENT

CONFIRMED 2025
SPEAKERS

AGENDA AT A
GLANCE

PRE-
CONFERENCE DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

2025 PARTNERS

PARTNER
WITH US

PRICING



REGISTER
NOW

Take the Spotlight: Partner with Us

Maximize Opportunities in the Advancing Field of Microbiome Therapeutics

As the microbiome’s role in human health continues to emerge as one of the most exciting frontiers in science, the discovery, development and commercialization of microbiome-based therapeutics must progress at an accelerated pace. With advancements spanning from discovery to clinical applications, the need for collaboration across the microbiome ecosystem is more critical than ever. ***This is where your expertise comes in.***

The **10th Microbiome Movement USA Summit** presents a unique opportunity for service providers to partner with innovators driving the future of microbiome therapeutics. By showcasing your expertise, you can help advance the field, from sequencing and bioinformatics to clinical research and manufacturing.

Key areas where you can make an impact:

Advance Microbiome Sequencing and Bioinformatics:

Provide innovative technologies and bioinformatics tools that enable comprehensive sequencing and data analysis of microbiome profiles, supporting the identification of novel therapeutic targets and predictive biomarkers for microbiome-related diseases

End-to-End Manufacturing Solutions for Microbiome Therapeutics:

Offer specialized contract manufacturing and development services to scale microbiome-based drug products, ensuring the consistency, quality, and regulatory compliance needed to move therapies from bench to market

Preclinical Research Models for Microbiome Drug Discovery:

Deliver *in vivo* and *in vitro* preclinical research services, including specialized microbiome models, that enable drug developers to evaluate the therapeutic potential and safety of microbiome-based interventions prior to clinical trials

Optimize Clinical Trials for Microbiome-Based Therapies:

Provide comprehensive clinical trial management services, including patient stratification, trial design, and data analysis, tailored to the unique challenges of microbiome drug development to ensure robust clinical evidence for therapeutic efficacy

Support Microbiome Research with High-Quality Reagents and Biobanks:


Supply essential reagents, culture systems, and biobank services to support microbiome research, facilitating the collection, preservation, and analysis of microbiome samples for use in drug development and clinical studies

Leverage this opportunity to position your company as a leader in the microbiome space. Place your brand at the forefront of microbiome research and connect with senior-level decision-makers from across the industry. Your organization can play a pivotal role to bring innovative microbiome therapeutics to market, improve patient outcomes, and shape the future of medicine.


“The sponsor-vendor ratio was favorable and made it easy for us to have conversations with potential customers. The on-site staff were helpful in making sure we were meeting with everyone we wanted to”

Kyle Arenofsky, Associate Director, Business Development, **Catawba Research**

Seniority:



Company Type:



*Statistics Taken from 9th Microbiome Movement USA Summit

JOIN 80+ MICROBIOME R&D REPRESENTATIVES

CONTENTS

- WHY JOIN IN 2025
- JOIN THE MICROBIOME MOVEMENT
- CONFIRMED 2025 SPEAKERS
- AGENDA AT A GLANCE
- PRE-CONFERENCE DAY
- CONFERENCE DAY ONE
- CONFERENCE DAY TWO
- 2025 PARTNERS
- PARTNER WITH US
- PRICING



REGISTER NOW



PROUD TO PARTNER WITH

Get Involved:



Oliver Smare
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com



LEAD PARTNER

Biose Industrie is a Contract Development and Manufacturing Organization (CDMO) specialised in Live Biotherapeutic Products. Founded in 1951 by pharmacists and microbiologists, Biose Industrie has been manufacturing drug substance and drug products based on microorganisms for 60 years. The company, with 10 000m² of GMP facility, offers product development at laboratory and pilot scale specialised in microbiology for aerobic and anaerobic strains and is Drug GMP certified for the manufacturing of API, clinical batches and commercial products.

www.biose.com



PROGRAM PARTNER

List Labs produced the first LBP for clinical trial, before LBP was even an acronym. Partner with List Labs as your CDMO and experience our uniquely collaborative and transparent culture built on 45 years of quality innovative drug development and manufacturing.

- Aerobes, anaerobes, and spore formers,
- Process development and scale up, analytical development and QC testing, purification, lyophilization
- Newly expanded encapsulation capacity, aseptic filling
- GMP manufacturing for clinical trials and future commercial launch

www.listlabs.com



EXHIBITION PARTNER

BA Sciences is a cGMP compliant, FDA/DEA registered, ISO/IEC-17025:2017 accredited pharmaceutical testing laboratory headquartered in Salem, NH. We provide the identity, purity, and potency analyses needed to characterize microbiome drug products. BA Sciences has a proven track record on a variety of Microbiome programs including spore fraction and defined drug product manufacturing processes. BA Sciences has invested in the latest equipment, including a MALDI-TOF mass spectrometer for microbial identification, and a Roche LightCycler® for qPCR.

www.basciences.com



EXHIBITION PARTNER

Anaerobe Systems, now part of Biolog, produces the world's only true pre-reduced anaerobically sterilized, TruPRAS™ culture media: poured and packaged under anaerobic conditions, as well as best-in-class anaerobic chambers. Founded over 40 years ago, for scientists by scientists, Anaerobe Systems has developed practical and efficient ways to optimize cultures of fastidious anaerobes. Biolog has the tools, services, and support to provide comprehensive cellular characterization and multi-omic identification for thousands of bacteria, yeast, and fungal species.

www.anaerobesystems.com



EVENT PARTNER

Greenberg Traurig, LLP (GT) has more than 2,850 attorneys across 49 locations in the US, Europe, the Middle East, Latin America, and Asia. The firm's broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2024 BTI "Leading Edge Law Firm" for anticipating and meeting client needs, GT is consistently ranked among the top firms on the Am Law Global 100 and NLJ 500

www.gtlaw.com

JOIN 80+
MICROBIOME R&D
REPRESENTATIVES

CONTENTS

WHY JOIN IN
2025

JOIN THE
MICROBIOME
MOVEMENT

CONFIRMED 2025
SPEAKERS

AGENDA AT A
GLANCE

PRE-
CONFERENCE DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

2025 PARTNERS

PARTNER
WITH US

PRICING



REGISTER
NOW

Ready to Register?

3 Easy Ways To Book

 www.microbiome-summit.com/take-part/register/

 Tel: +1 617 455 4188

 Email: info@hansonwade.com

Team Discounts

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

**Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

- 1 DISCOVER** how pioneering companies are leveraging microbiome-driven insights to revolutionize the development of next-generation microbiome-based therapeutics with **Concerto Biosciences**, **Kanvas Bio**, and **Jona**.
- 2 BUILD** a deeper understanding of the challenges and opportunities in microbiome drug discovery, from biomarker identification to clinical application with **Ferring Pharmaceuticals**, **MaaT Pharma**, and **Siolta Therapeutics**.
- 3 ENGAGE** with top-tier professionals from pharma, biotech, and research organizations to foster collaborations, share knowledge, and drive innovation in microbiome therapeutics

Drug Developer's Pricing	Standard Rate (Save \$100)	On the Door Price	Start-Up & Academic's Pricing	Standard Rate (Save \$100)	On the Door Price	Service & Solution Provider Pricing	Standard Rate (Save \$100)	On the Door Price
Conference + Workshop Day	\$4,097	\$4,197	Conference + Workshop Day	\$2,797	\$2,897	Conference + Workshop Day	\$4,997	\$5,097
Conference Only	\$2,899	\$2,999	Conference Only	\$2,099	\$2,199	Conference Only	\$3,599	\$3,699

*To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

Venue

Revere Hotel Boston Common
200 Stuart Street, Boston, MA 02116, United States

For further information or assistance, please visit: www.reverehotel.com

JOIN 80+
MICROBIOME R&D
REPRESENTATIVES

CONTENTS

WHY JOIN IN
2025

JOIN THE
MICROBIOME
MOVEMENT

CONFIRMED 2025
SPEAKERS

AGENDA AT A
GLANCE

PRE-
CONFERENCE DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

2025 PARTNERS

PARTNER
WITH US

PRICING



REGISTER
NOW